Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Shares Issued (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Shares Issued data on record, last reported at -$48000.0 in Q4 2025.

  • For Q4 2025, Shares Issued fell 111.85% year-over-year to -$48000.0; the TTM value through Dec 2025 reached $219000.0, up 100.2%, while the annual FY2025 figure was $219000.0, 45.93% down from the prior year.
  • Shares Issued reached -$48000.0 in Q4 2025 per CTNM's latest filing, down from $243000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $405000.0 in Q4 2024 and bottomed at -$107.9 million in Q2 2024.
  • Average Shares Issued over 3 years is -$11.9 million, with a median of $19000.0 recorded in 2023.
  • The widest YoY moves for Shares Issued: up 1425.0% in 2024, down 567994.74% in 2024.
  • A 3-year view of Shares Issued shows it stood at -$27000.0 in 2023, then surged by 1600.0% to $405000.0 in 2024, then plummeted by 111.85% to -$48000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Issued were -$48000.0 in Q4 2025, $243000.0 in Q2 2025, and $24000.0 in Q1 2025.